vs
Side-by-side financial comparison of DIODES INC (DIOD) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $391.6M, roughly 1.8× DIODES INC). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 2.6%, a 16.5% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 15.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $12.4M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 13.9%).
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
DIOD vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $391.6M | $708.5M |
| Net Profit | $10.2M | $135.1M |
| Gross Margin | 31.1% | — |
| Operating Margin | 3.4% | 21.6% |
| Net Margin | 2.6% | 19.1% |
| Revenue YoY | 15.4% | 32.0% |
| Net Profit YoY | 23.8% | 15.5% |
| EPS (diluted) | $0.23 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $391.6M | $708.5M | ||
| Q3 25 | $392.2M | $659.9M | ||
| Q2 25 | $366.2M | $603.3M | ||
| Q1 25 | $332.1M | $558.6M | ||
| Q4 24 | $339.3M | $536.6M | ||
| Q3 24 | $350.1M | $533.3M | ||
| Q2 24 | $319.8M | $528.1M | ||
| Q1 24 | $302.0M | $511.0M |
| Q4 25 | $10.2M | $135.1M | ||
| Q3 25 | $14.3M | $111.1M | ||
| Q2 25 | $46.1M | $90.3M | ||
| Q1 25 | $-4.4M | $114.6M | ||
| Q4 24 | $8.2M | $117.0M | ||
| Q3 24 | $13.7M | $96.4M | ||
| Q2 24 | $8.0M | $88.4M | ||
| Q1 24 | $14.0M | $102.6M |
| Q4 25 | 31.1% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 31.5% | — | ||
| Q1 25 | 31.5% | — | ||
| Q4 24 | 32.7% | — | ||
| Q3 24 | 33.7% | — | ||
| Q2 24 | 33.6% | — | ||
| Q1 24 | 33.0% | — |
| Q4 25 | 3.4% | 21.6% | ||
| Q3 25 | 3.0% | 21.5% | ||
| Q2 25 | 2.6% | 20.9% | ||
| Q1 25 | 0.4% | 20.3% | ||
| Q4 24 | 3.5% | 23.4% | ||
| Q3 24 | 6.2% | 21.1% | ||
| Q2 24 | 1.2% | 19.9% | ||
| Q1 24 | 4.3% | 20.4% |
| Q4 25 | 2.6% | 19.1% | ||
| Q3 25 | 3.6% | 16.8% | ||
| Q2 25 | 12.6% | 15.0% | ||
| Q1 25 | -1.3% | 20.5% | ||
| Q4 24 | 2.4% | 21.8% | ||
| Q3 24 | 3.9% | 18.1% | ||
| Q2 24 | 2.5% | 16.7% | ||
| Q1 24 | 4.6% | 20.1% |
| Q4 25 | $0.23 | $4.65 | ||
| Q3 25 | $0.31 | $3.86 | ||
| Q2 25 | $0.99 | $3.10 | ||
| Q1 25 | $-0.10 | $3.67 | ||
| Q4 24 | $0.18 | $3.67 | ||
| Q3 24 | $0.30 | $3.01 | ||
| Q2 24 | $0.17 | $2.75 | ||
| Q1 24 | $0.30 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $497.0M |
| Total DebtLower is stronger | $25.7M | — |
| Stockholders' EquityBook value | $1.9B | $459.1M |
| Total Assets | $2.4B | $2.0B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $377.0M | $497.0M | ||
| Q3 25 | $386.4M | $285.4M | ||
| Q2 25 | $327.3M | $46.3M | ||
| Q1 25 | $343.9M | $441.4M | ||
| Q4 24 | $316.1M | $669.4M | ||
| Q3 24 | $319.3M | $656.9M | ||
| Q2 24 | $273.9M | $510.9M | ||
| Q1 24 | $276.0M | $407.0M |
| Q4 25 | $25.7M | — | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $26.4M | — | ||
| Q1 25 | $20.5M | — | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | $1.9B | $459.1M | ||
| Q3 25 | $1.9B | $293.6M | ||
| Q2 25 | $1.9B | $172.4M | ||
| Q1 25 | $1.8B | $593.6M | ||
| Q4 24 | $1.8B | $825.5M | ||
| Q3 24 | $1.8B | $881.4M | ||
| Q2 24 | $1.8B | $763.6M | ||
| Q1 24 | $1.7B | $671.5M |
| Q4 25 | $2.4B | $2.0B | ||
| Q3 25 | $2.5B | $1.8B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.4B | $1.9B | ||
| Q4 24 | $2.4B | $2.1B | ||
| Q3 24 | $2.4B | $2.1B | ||
| Q2 24 | $2.4B | $1.9B | ||
| Q1 24 | $2.4B | $1.8B |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.1M | $192.7M |
| Free Cash FlowOCF − Capex | $12.4M | $188.1M |
| FCF MarginFCF / Revenue | 3.2% | 26.6% |
| Capex IntensityCapex / Revenue | 6.6% | 0.6% |
| Cash ConversionOCF / Net Profit | 3.74× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $137.2M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.1M | $192.7M | ||
| Q3 25 | $79.1M | $246.2M | ||
| Q2 25 | $41.5M | $148.5M | ||
| Q1 25 | $56.7M | $125.8M | ||
| Q4 24 | $81.8M | $190.7M | ||
| Q3 24 | $54.4M | $149.1M | ||
| Q2 24 | $14.4M | $116.4M | ||
| Q1 24 | $-31.1M | $152.7M |
| Q4 25 | $12.4M | $188.1M | ||
| Q3 25 | $62.8M | $235.5M | ||
| Q2 25 | $21.1M | $142.4M | ||
| Q1 25 | $40.8M | $115.8M | ||
| Q4 24 | $62.1M | $183.0M | ||
| Q3 24 | $39.4M | $138.5M | ||
| Q2 24 | $-3.5M | $103.5M | ||
| Q1 24 | $-51.5M | $147.2M |
| Q4 25 | 3.2% | 26.6% | ||
| Q3 25 | 16.0% | 35.7% | ||
| Q2 25 | 5.8% | 23.6% | ||
| Q1 25 | 12.3% | 20.7% | ||
| Q4 24 | 18.3% | 34.1% | ||
| Q3 24 | 11.2% | 26.0% | ||
| Q2 24 | -1.1% | 19.6% | ||
| Q1 24 | -17.1% | 28.8% |
| Q4 25 | 6.6% | 0.6% | ||
| Q3 25 | 4.2% | 1.6% | ||
| Q2 25 | 5.6% | 1.0% | ||
| Q1 25 | 4.8% | 1.8% | ||
| Q4 24 | 5.8% | 1.4% | ||
| Q3 24 | 4.3% | 2.0% | ||
| Q2 24 | 5.6% | 2.4% | ||
| Q1 24 | 6.7% | 1.1% |
| Q4 25 | 3.74× | 1.43× | ||
| Q3 25 | 5.54× | 2.22× | ||
| Q2 25 | 0.90× | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | 9.93× | 1.63× | ||
| Q3 24 | 3.95× | 1.55× | ||
| Q2 24 | 1.80× | 1.32× | ||
| Q1 24 | -2.22× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
